Gastroesophageal Cancer clinical trials

Explore recruiting gastroesophageal cancer clinical trials.

Recruiting gastroesophageal cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastroesophageal Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Norway, Italy, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Germany, Italy, Norway, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Gastroesophageal Cancer trials by city

Gastroesophageal Cancer clinical trials

Recruiting gastroesophageal cancer studies right now

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

Nivolumab Combined With SOX Used in the Perioperative Treatment

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Also recruiting in Europe

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial

NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study

Gastroesophageal Cancer trials by city

Other conditions